The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

There's new evidence the class of drugs that includes Ozempic may have health benefits that go beyond diabetes treatment and weight loss. A major new study suggests these drugs could help with dozens ...

One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes ...

A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

People with type 2 diabetes had significantly fewer heart attacks, strokes, heart failures, and deaths from cardiovascular ...